Retatrutide is not approved as a medicine anywhere in the world as of October 2026, including Canada. Eli Lilly has finished five positive phase 3 trials and plans to file with the FDA in the first quarter of 2027; a Health Canada submission would normally follow. Until then, the only retatrutide sold in Canada is research-grade material, which is legal to sell for laboratory research but is not a drug and is not for human use.
If you are sourcing it for research, the questions that matter are identity (is it actually retatrutide?), purity, fill accuracy and how it travelled. This guide covers the legal picture, what Health Canada has said, how to read a retatrutide certificate of analysis, and the red flags that separate a real supplier from a reseller.
What retatrutide is, in one minute
Retatrutide (Eli Lilly code LY3437943) is a single peptide built to activate three hormone receptors at once: GLP-1, GIP and glucagon. Semaglutide (Ozempic, Wegovy) activates one of those, and tirzepatide (Mounjaro, Zepbound) two. That is why retatrutide gets called a “triple agonist” and, in online slang, “GLP-3”, a nickname with no scientific meaning.
The glucagon component is the interesting part. Glucagon normally raises blood sugar, which sounds like the opposite of what you want in an obesity drug. But it also increases energy expenditure and pulls fat out of the liver. Combined with GLP-1 and GIP signalling to offset the blood sugar effect, the result in trials has been the largest average weight loss ever reported for a drug.
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Receptors | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + glucagon |
| Approved in Canada? | Yes (Ozempic, Wegovy, generics since 2026) | Yes (Mounjaro, Zepbound) | No |
| Best average weight loss in a phase 3 trial | About 15% (STEP 1) | About 21% (SURMOUNT-1) | 28.3% at 80 weeks (TRIUMPH-1) |
| Status, October 2026 | Marketed | Marketed | FDA filing planned Q1 2027 |
For the trial-by-trial detail, see Retatrutide phase 3 results explained. This article is about the Canadian side: legality, sourcing and verification.
Is retatrutide legal in Canada?
The honest answer has two parts, and most websites only give you one.
As a medicine: no. Retatrutide has no Drug Identification Number (DIN), no Notice of Compliance, and no marketing authorization from Health Canada. No doctor can prescribe it as an approved drug and no pharmacy can dispense it. Selling it for human use, advertising it as a treatment, or importing it to inject is not permitted under the Food and Drugs Act.
As a research chemical: it is sold. Canadian law does not ban the peptide molecule itself. Retatrutide is not a controlled substance under the Controlled Drugs and Substances Act. Suppliers sell it as a laboratory reagent, labelled for in vitro research, with no therapeutic claims. That is the category TrueLabs operates in, and it is the same category as most research peptides on the Canadian market.
The legal distinction is about intended use and claims, not the molecule. A supplier that tells you how much to inject, promises weight loss or sells “pens” is marketing an unauthorized drug. A legitimate research supplier does none of those things, and you should treat any that does as a red flag rather than a convenience.
This is also why you will not find dosing instructions on this page or anywhere on TrueLabs. Not because the information is secret (the trial doses are published in the medical literature) but because giving personal-use guidance for an unapproved drug is precisely what turns a research reagent into an illegal medicine.
What Health Canada has actually said
Health Canada has become noticeably more active on peptides over the past 18 months. Two actions are worth knowing.
August 2025: the Canada Peptide seizure
In advisory RA-77807 (August 1, 2025), Health Canada announced it had seized unauthorized injectable peptide drugs sold by a company called Canada Peptide, and warned that the products may pose serious health risks. The list of more than 40 products named retatrutide and tirzepatide alongside BPC-157, TB-500 and others. The issue was not that peptides exist; it was that they were being sold in a way that presented them as injectable drugs for people.
April 2026: “Think twice before injecting peptides bought online”
On April 9, 2026, Health Canada issued a public advisory warning Canadians against injecting peptides bought online. The advisory makes three points worth repeating:
- Unauthorized products have not been assessed for safety, effectiveness or quality.
- They may contain the wrong ingredient, the wrong amount, or contaminants, including bacteria.
- Health Canada works with the Canada Border Services Agency to stop unauthorized shipments at the border.
Read as a researcher, the advisory is also a quality checklist: wrong ingredient (identity), wrong amount (fill accuracy), contamination (purity, sterility, endotoxin). The rest of this guide is built around exactly those three failure modes.
When could approved retatrutide reach Canada?
Here is the realistic timeline, based on Lilly’s public statements and how past obesity drugs moved through Health Canada.
| Milestone | Status / estimate |
|---|---|
| Phase 2 obesity trial published (NEJM) | June 2023 |
| TRIUMPH-4 (knee arthritis) topline | December 2025 |
| TRIUMPH-1 topline (28.3% at 80 weeks) | May–June 2026 |
| TRIUMPH-2 and TRIUMPH-3 topline | July 2026 |
| FDA submission | Planned Q1 2027 |
| FDA decision | Plausibly late 2027 to 2028 (standard review is about 10–12 months) |
| Health Canada decision | Typically 6–18 months after the US, depending on when Lilly files here |
For context: Wegovy was approved by the FDA in June 2021 and became available in Canadian pharmacies in May 2024. Zepbound reached Canada in May 2025, about 18 months after its US approval. A realistic expectation for prescription retatrutide in Canada is therefore 2028 at the earliest, with public and private coverage coming later still. Health Canada publishes a list of new drug submissions under review; as of its most recent update, retatrutide was not on it.
We track the approval story separately in Is retatrutide approved?, which we update when anything changes.
What “research use only” really means
“For research use only” (RUO) is printed on a lot of vials, and it is easy to read it as a wink. It isn’t, and understanding why helps you judge suppliers.
A research reagent is made to a specification (identity, purity, content) and sold to people running experiments: cell culture, receptor binding assays, analytical method development, animal work under appropriate oversight. It is not made under Good Manufacturing Practice (GMP) for human drugs, not filled in a sterile pharmaceutical suite, and not tested for every attribute a drug must pass. That is fine for a cell assay. It is a serious problem if someone injects it, which is exactly Health Canada’s point.
| Attribute | Approved drug (e.g. Zepbound) | Research-grade peptide |
|---|---|---|
| Manufacturing standard | GMP, inspected by regulators | Synthesis to a research specification |
| Sterility | Validated sterile fill | Not guaranteed |
| Endotoxin | Tested to strict limits | Sometimes tested; often not |
| Identity and purity | Fully characterized | Depends entirely on the supplier’s testing |
| Who it is for | Patients, via a prescriber | Laboratory research |
A supplier that is serious about the research market behaves accordingly: it publishes batch testing, does not make health claims, does not provide human dosing, and will not ship “kits” designed for self-injection.
Why retatrutide is harder to make than BPC-157
Not all peptides are equally easy to get right, and this is the single most under-appreciated point in the research peptide market.
BPC-157 is 15 amino acids long. Retatrutide is 39 amino acids with several non-standard residues and a fatty-acid side chain attached to extend its half-life. Its molecular weight is roughly 4.7 kDa, more than three times BPC-157’s.
Every extra amino acid in solid-phase synthesis is another coupling step where things can go wrong. If each step is 99% efficient, a 15-mer comes out about 86% correct before purification, while a 39-mer comes out about 68% correct. The failures are not random junk; they are near-identical peptides missing one residue (deletion sequences) or carrying a damaged one. These impurities can look similar on a basic purity test, which is why identity confirmation by mass spectrometry matters so much more for long peptides.
Longer, lipidated peptides cost more to make, cost more to purify and lose more material along the way. A retatrutide vial priced like BPC-157 isn’t a bargain. It is a question you should ask out loud.
How to verify a retatrutide supplier
There are five things to check, in order of importance.
- A batch-specific certificate of analysis (COA). Not a generic “example” document, but a COA whose batch or lot number matches what you will receive.
- Identity by mass spectrometry. The COA should show a measured mass that matches retatrutide’s expected mass. Without this, an HPLC purity number only tells you that something is pure.
- Purity by HPLC. Look for a chromatogram, not just a number. A single dominant peak with a stated purity (research-grade material is commonly in the high 90s) is what you want.
- Content or fill. Does a “10 mg” vial contain about 10 mg of peptide? Some COAs report net peptide content or quantity per vial; many don’t, and under-filling is one of the most common problems found by independent testers.
- Who did the testing. A named laboratory you can contact is worth more than an unbranded PDF.
Our detailed walkthrough of these documents is in How to read a peptide COA, and you can compare it against real documents in the TrueLabs COA library.
Reading a retatrutide COA line by line
A good COA for a long peptide like retatrutide will contain most of the following fields. Here is what each one tells you, and what a weak COA leaves out.
| Field | What it tells you | Watch for |
|---|---|---|
| Product name and batch/lot number | Which material was tested | No batch number = no traceability |
| Test date | How recent the analysis is | Dates years old for a “fresh” batch |
| Appearance | White to off-white lyophilized powder | Yellowing or a collapsed cake can indicate degradation or moisture |
| Purity (HPLC) | Percentage of the main peak | A number with no chromatogram |
| Identity (MS) | Measured mass vs theoretical mass | “Conforms” with no measured value |
| Quantity / content | Milligrams per vial | Missing entirely |
| Testing laboratory | Who ran the analysis | Logo-only, no address, no contact |
Mass spec: the test that proves identity
If you take one technical idea from this guide, take this one. HPLC tells you how pure a sample is. Mass spectrometry tells you what it is.
An HPLC trace separates the components of a sample and measures how much of the total is in the main peak. But HPLC doesn’t identify the main peak. A vial of the wrong peptide (say, a cheaper GLP-1 analogue sold as retatrutide) can show 99% purity on HPLC.
Mass spectrometry weighs the molecules. Large peptides pick up several charges in the instrument, so a retatrutide spectrum usually shows a cluster of peaks at different charge states that, when deconvoluted, give back a single mass near the theoretical value. When a COA shows that measured mass alongside the expected one, you have evidence of identity. When it only says “MS: conforms”, you have a claim.
Ask the supplier for the full MS report behind a COA. Suppliers that test properly can usually send it within a day. Suppliers working from a template can’t.
Red flags
- Dosing charts, “protocols” or weight-loss promises. These mean the seller is marketing a drug, which makes them more exposed to enforcement, and suggests the rest of their compliance is loose too.
- Pre-filled pens or “ready to inject” kits. No legitimate research supplier sells these.
- No batch number on the COA, or the same COA used for every batch over a year.
- Prices far below the market. A 39-residue lipidated peptide cannot be made cheaply. A large discount usually means under-filling, a substitute compound, or both.
- Card payments for peptides. Card networks do not process for this category; a site taking Visa may be miscoding transactions, which is a risk to you.
- Shipping from overseas with a “guaranteed delivery” promise. Nobody can guarantee what CBSA will do.
- Brand names on the vial (“Reta-Zep”, “GLP-3 Max”). Research reagents are labelled with the compound, quantity and batch.
We cover counterfeit detection more broadly in How to spot fake peptides.
Domestic vs imported: customs, seizures and cold chain
Many Canadians order retatrutide directly from overseas vendors because the listed price looks lower. Three things change the maths.
1. Seizure risk
Health Canada has said publicly that it works with CBSA to stop unauthorized peptide shipments. A seized parcel is a 100% loss, and repeat shipments to the same address can draw more scrutiny. A domestic supplier ships within Canada, so there is no border to cross.
2. Brokerage and time
Imported parcels can incur brokerage fees and duties, and international transit for lyophilized peptides commonly runs one to three weeks. TrueLabs ships within Canada with tracked delivery, usually in 2–4 business days.
3. Temperature
Freeze-dried peptides are reasonably robust at room temperature for short periods, but long-chain peptides sitting in a hot warehouse or a customs facility for weeks are a different matter. Short transit is part of quality, not just convenience.
The full comparison is in Canadian vs imported peptides.
Vial sizes and price per milligram
TrueLabs sells retatrutide as RT3 Retatrutide in 10 mg, 30 mg and 60 mg vials, starting at $90. Larger vials lower the cost per milligram, which matters for longer research programs, but only if the material will be used before it degrades once reconstituted.
| Question | Why it matters |
|---|---|
| How many mg does the experiment actually need? | Buying a 60 mg vial for a short assay wastes most of it once reconstituted. |
| Will it be reconstituted all at once? | Reconstituted peptides have a much shorter shelf life than powder. |
| Does the order clear the free-shipping threshold? | Standard domestic shipping is $19, free over $200. |
For a broader view across compounds, see our Canadian peptide price guide.
Storage for laboratory work
Storage is where good material quietly turns into bad material. The general principles for lyophilized peptides apply to retatrutide:
- Powder: keep sealed, dry and cold. A freezer (−20 °C) is best for long-term storage; a refrigerator is fine for weeks.
- Avoid moisture. Let a cold vial reach room temperature before opening it so condensation doesn’t form on the powder.
- Avoid light and heat. Don’t leave vials on a sunny bench or in a car.
- Once reconstituted: refrigerate, protect from light, and avoid repeated freeze–thaw cycles, which can damage long peptides.
More detail, including how bacteriostatic and sterile water differ for lab use, is in How to store peptides and Bacteriostatic vs sterile water.
Retatrutide vs tirzepatide vs semaglutide for researchers
Why would a lab choose retatrutide over a two-receptor or one-receptor compound? It depends on the question.
| Research question | Most useful compound |
|---|---|
| Pure GLP-1 receptor pharmacology | Semaglutide |
| What GIP adds to GLP-1 | Tirzepatide vs semaglutide |
| What glucagon receptor activity adds (energy expenditure, liver fat) | Retatrutide vs tirzepatide |
| Amylin pathway in combination | Cagrilintide |
Retatrutide is especially useful for liver research. In a phase 2a sub-study published in Nature Medicine in 2024, most participants on the higher doses saw liver fat normalize by 48 weeks. That makes it a reference compound for studies on metabolic dysfunction-associated steatotic liver disease (MASLD). TrueLabs also carries TZ-2 (tirzepatide) for comparison work. Our head-to-head summary is in Retatrutide vs tirzepatide vs semaglutide.
Names you will see: RT3, LY3437943, “reta”
Retatrutide goes by several names online, which causes confusion when comparing suppliers:
- LY3437943: Eli Lilly’s development code, used in trial registries and early papers.
- RT3, R3, “reta”: shorthand used by research suppliers and forums.
- “GLP-3”: marketing slang. There is no GLP-3 hormone. Products sold under this name sometimes contain something else entirely.
- “Triple G”: a nickname for the triple-agonist mechanism.
Whatever the name on the label, the COA should identify the compound as retatrutide and show its mass.
A pre-order checklist
- The supplier is in Canada and ships domestically.
- A batch-specific COA is available before purchase.
- The COA includes HPLC purity and mass spectrometry identity.
- The testing lab is named.
- The price per milligram is in line with other reputable suppliers.
- The site makes no health claims and gives no human dosing.
- Payment is by Interac e-Transfer, the standard for this category in Canada.
- You have a plan to store the material cold and dry on arrival.
Five myths about retatrutide in Canada
“It’s legal because it’s sold openly.”
Selling a research reagent is legal; that doesn’t make it legal to sell or use as a medicine. The distinction is what lets legitimate suppliers operate, and it’s also what Health Canada enforces against.
“A doctor can prescribe it off-label.”
Off-label prescribing applies to drugs that are approved for something. Retatrutide isn’t approved for anything, so there is no label to go off.
“Compounding pharmacies can make it.”
Not legitimately in Canada. Pharmacy compounding uses authorized ingredients for individual patients; an investigational drug substance isn’t one of them. The US debate over compounded peptides (including the FDA advisory committee votes in July 2026) concerned other peptides, not retatrutide.
“Higher purity on the label means it’s real.”
Purity without identity can describe a pure sample of the wrong peptide. See the mass spec section above.
“It will be on pharmacy shelves in 2027.”
The FDA filing is planned for 2027. Approval, then a Canadian submission and review, push realistic Canadian availability to 2028 or later.
FAQ
Tap a question to reveal the answer.
Is retatrutide legal in Canada?
It is not approved as a drug in Canada or anywhere else as of October 2026. Research-grade retatrutide is sold legally in Canada as a laboratory reagent, for in vitro research only, without therapeutic claims. Selling or importing it for human use is not permitted.
Can a Canadian doctor prescribe retatrutide?
No. Because it has no Health Canada authorization, there is no approved product to prescribe. Access to retatrutide for people is currently limited to clinical trials.
When will retatrutide be approved in Canada?
Eli Lilly plans to file with the FDA in the first quarter of 2027. Canadian approval usually follows a US approval by months to more than a year, so 2028 is a realistic earliest estimate.
What is RT3?
RT3 is shorthand for retatrutide used by research suppliers. TrueLabs sells retatrutide under the name RT3 Retatrutide, in 10, 30 and 60 mg vials.
How do I know research retatrutide is real?
Ask for a batch-specific certificate of analysis that shows both HPLC purity and a mass spectrometry result matching retatrutide’s expected molecular mass, from a named laboratory. HPLC alone can’t confirm identity.
Is it safe to order retatrutide from overseas?
Imported peptide shipments can be stopped by the Canada Border Services Agency, which Health Canada says it works with to block unauthorized peptides. Imports also face longer transit, temperature exposure and possible brokerage fees. Domestic suppliers avoid the border entirely.
How should research retatrutide be stored?
Keep the freeze-dried powder sealed, dry and cold, ideally frozen for long-term storage. Once reconstituted, refrigerate it, protect it from light and avoid repeated freezing and thawing.
Is retatrutide the same as “GLP-3”?
“GLP-3” is an informal nickname. There is no GLP-3 hormone. Products sold under that name are not always retatrutide, which is another reason to insist on mass spectrometry identity testing.
Related reading
- Retatrutide phase 3 results explained
- Is retatrutide approved?
- Is retatrutide safe?
- Common retatrutide research mistakes
- Peptides for weight loss: the evidence, compound by compound
- Research peptides in Canada
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389:514–526. PubMed
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037–2048. PubMed
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, successful in two additional phase 3 obesity trials. Press release, July 23, 2026. Lilly
- AJMC. Retatrutide achieves up to 30.3% average weight loss in phase 3 TRIUMPH-1 trial. May 2026. AJMC
- Health Canada. Think twice before injecting peptides bought online. Public advisory, April 9, 2026. Health Canada
- Health Canada. Advisory RA-77807: Unauthorized injectable peptide drugs seized and sold by Canada Peptide. August 1, 2025. Recalls and Safety Alerts
- Health Canada. New drug submissions under review. Health Canada
This article is for information only and is not medical or legal advice. Retatrutide is an investigational drug that is not approved in Canada. TrueLabs research compounds are sold for in vitro and laboratory research use only and are not intended for human or veterinary use.